IL100904A - Pharmaceuticals containing rapamycin for the treatment of systemic lupus erythematosus - Google Patents

Pharmaceuticals containing rapamycin for the treatment of systemic lupus erythematosus

Info

Publication number
IL100904A
IL100904A IL10090492A IL10090492A IL100904A IL 100904 A IL100904 A IL 100904A IL 10090492 A IL10090492 A IL 10090492A IL 10090492 A IL10090492 A IL 10090492A IL 100904 A IL100904 A IL 100904A
Authority
IL
Israel
Prior art keywords
rapamycin
csa
treated
mrl
sle
Prior art date
Application number
IL10090492A
Other languages
English (en)
Hebrew (he)
Other versions
IL100904A0 (en
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of IL100904A0 publication Critical patent/IL100904A0/xx
Publication of IL100904A publication Critical patent/IL100904A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
IL10090492A 1991-02-22 1992-02-10 Pharmaceuticals containing rapamycin for the treatment of systemic lupus erythematosus IL100904A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/660,470 US5078999A (en) 1991-02-22 1991-02-22 Method of treating systemic lupus erythematosus

Publications (2)

Publication Number Publication Date
IL100904A0 IL100904A0 (en) 1992-11-15
IL100904A true IL100904A (en) 1995-10-31

Family

ID=24649665

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10090492A IL100904A (en) 1991-02-22 1992-02-10 Pharmaceuticals containing rapamycin for the treatment of systemic lupus erythematosus

Country Status (21)

Country Link
US (1) US5078999A (da)
EP (1) EP0572542B9 (da)
KR (1) KR100201517B1 (da)
AT (1) ATE202938T1 (da)
AU (1) AU664545B2 (da)
CA (1) CA2103568A1 (da)
CY (1) CY2305B1 (da)
DE (1) DE69231927T2 (da)
DK (1) DK0572542T3 (da)
ES (1) ES2157901T3 (da)
GR (1) GR3036477T3 (da)
HK (1) HK1011281A1 (da)
HU (1) HUT70489A (da)
IE (1) IE920556A1 (da)
IL (1) IL100904A (da)
MX (1) MX9200727A (da)
NZ (1) NZ241671A (da)
PT (1) PT100145B (da)
SG (1) SG52404A1 (da)
WO (1) WO1992014477A1 (da)
ZA (1) ZA921210B (da)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5164399A (en) * 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5262424A (en) * 1992-02-18 1993-11-16 American Home Products Corporation Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
EP0562853B1 (en) 1992-03-27 1996-06-05 American Home Products Corporation 29-Demethoxyrapamycin for inducing immunosuppression
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5482945A (en) * 1992-12-22 1996-01-09 American Home Products Corporation Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
EP0710110B1 (en) 1993-04-23 2002-03-06 Abbott Laboratories Antibodies of ring opened rapamycins
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
AU2001249182A1 (en) * 2000-03-14 2001-09-24 Genetics Institute Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
DK1319008T3 (da) 2000-09-19 2009-02-09 Wyeth Corp Vandoplöselige rapamycinestere
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
BR0211905A (pt) 2001-08-22 2004-09-21 Wyeth Corp Dialdeìdos de rapamicina
CN1310908C (zh) 2001-08-22 2007-04-18 惠氏公司 雷帕霉素29－烯醇
RU2344821C2 (ru) * 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
KR20050084559A (ko) * 2002-09-17 2005-08-26 와이어쓰 경구 제형
WO2004027027A2 (en) 2002-09-18 2004-04-01 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
WO2004036221A2 (en) * 2002-10-18 2004-04-29 Wyeth Compositions and methods for diagnosing and treating autoimmune disease
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
EP1615640B1 (en) * 2003-04-22 2007-01-24 Wyeth Antineoplastic combinations
CN1882338A (zh) * 2003-09-18 2006-12-20 马库赛特公司 经巩膜递送
DE602005010228D1 (de) 2004-04-14 2008-11-20 Wyeth Corp Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
CA2582374A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20060258698A1 (en) * 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
AU2006214021A1 (en) * 2005-02-15 2006-08-24 Wyeth Orally bioavailable CCI-779 tablet formulations
WO2007059106A2 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of mntor inhibitor to treat patients with cancer
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
MX2009001857A (es) * 2006-08-22 2009-03-02 Novartis Ag Tratamiento de trastornos fibrosantes.
EP2702993B1 (en) 2006-09-13 2017-12-06 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
KR20110074758A (ko) * 2008-10-03 2011-07-01 엘릭서 메디컬 코포레이션 마크로사이클릭 락톤 화합물 및 이를 사용하는 방법
CN104042612A (zh) 2008-11-11 2014-09-17 得克萨斯大学体系董事会 哺乳动物雷帕霉素靶蛋白的抑制
ES2685947T3 (es) 2009-04-10 2018-10-15 Haiyan Qi Agentes antienvejecimiento
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US20150290176A1 (en) 2012-10-12 2015-10-15 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体

Also Published As

Publication number Publication date
AU664545B2 (en) 1995-11-23
KR100201517B1 (ko) 1999-06-15
EP0572542A1 (en) 1993-12-08
DK0572542T3 (da) 2001-09-17
WO1992014477A1 (en) 1992-09-03
PT100145B (pt) 1999-06-30
EP0572542B1 (en) 2001-07-11
DE69231927T2 (de) 2001-11-22
SG52404A1 (en) 1998-09-28
MX9200727A (es) 1992-09-01
IE920556A1 (en) 1992-08-26
IL100904A0 (en) 1992-11-15
US5078999A (en) 1992-01-07
CA2103568A1 (en) 1992-08-23
ES2157901T3 (es) 2001-09-01
PT100145A (pt) 1993-08-31
DE69231927D1 (de) 2001-08-16
AU1469192A (en) 1992-09-15
HK1011281A1 (en) 1999-07-09
CY2305B1 (en) 2003-07-04
KR930703001A (ko) 1993-11-29
ZA921210B (en) 1993-08-19
ATE202938T1 (de) 2001-07-15
EP0572542B9 (en) 2001-11-21
GR3036477T3 (en) 2001-11-30
EP0572542A4 (en) 1994-06-01
HUT70489A (en) 1995-10-30
NZ241671A (en) 1997-06-24

Similar Documents

Publication Publication Date Title
EP0572542B1 (en) Method of treating systemic lupus erythematosus
IE83403B1 (en) Method for treating systemic lupus erythematosus
Benito et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease1
Hollenbach et al. Inhibition of p38 MAP kinase‐and RICK/NF‐κB‐signaling suppresses inflammatory bowel disease
Wofsy et al. Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene.
CA2103571C (en) Method of treating pulmonary inflammation
Sihra et al. Effect of cyclosporin A on the allergen-induced late asthmatic reaction.
IE61232B1 (en) Medicaments to combat chronic graft-versus-host diseases and to combat autoimmune diseases, in particular systemic lupus erythematosus
US5679709A (en) Medicaments to combat autoimmune diseases
Bousvaros et al. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506)
NL8802634A (nl) Therapeutische preparaten.
Casolaro et al. In vivo characterization of the anti-inflammatory effect of cyclosporin A on human basophils.
US20230014231A1 (en) Methods for treating neutropenia
EP0744949A1 (en) Treatment and/or prevention of type i diabetes mellitus with gamma interferon administration
WO2009127048A1 (en) Method of treating demyelinating diesase
Melink et al. Phase I Evaluation and Pharmacokinetics of Tiazofurin (2-β-d-Ribofuranosylthiazole-4-carboxamide, NSC 286193)
EP0561772A1 (en) A new pharmaceutical use of fusidic acid and derivatives thereof
Kyles et al. Comparison of the in vitro antiproliferative effects of five immunosuppressive drugs on lymphocytes in whole blood from cats
EP0772442B1 (en) Use of immunosuppressive agents for the treatment of schizophrenia
Saito A case of systemic lupus erythematosus complicated with multicentric reticulohistiocytosis (MRH): successful treatment of MRH and lupus nephritis with cyclosporin A
KR20220147013A (ko) 피리메타민을 유효성분으로 포함하는 류마티스 관절염의 치료 또는 예방용 약학 조성물
Hedges et al. Ciclosporin‐Dependent, nu‐Independent, Mucosal Interleukin 6 Response to Gram‐Negative Bacteria
Kay Immunosuppressive agents in chronic severe asthma
Pahl et al. Anti-inflammatory effects of a cyclosporine receptor-binding compound, D-43787
WO2023277491A1 (ko) 면역 억제 t 세포를 포함하는 면역 관련 질환의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HCA Change of name of proprietor(s) after amalgamation
MM9K Patent not in force due to non-payment of renewal fees